147 related articles for article (PubMed ID: 35435571)
21. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
[TBL] [Abstract][Full Text] [Related]
22. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma.
Vo TN; Meric-Bernstam F; Yi M; Buchholz TA; Ames FC; Kuerer HM; Bedrosian I; Hunt KK
Am J Surg; 2006 Oct; 192(4):552-5. PubMed ID: 16978974
[TBL] [Abstract][Full Text] [Related]
24. Impact of neoadjuvant and adjuvant chemotherapy on invasive lobular carcinoma: A propensity score-matched analysis of SEER data.
Watanuki R; Hayashida T; Yokoe T; Kawai Y; Kikuchi M; Nakashoji A; Nagayama A; Seki T; Takahashi M; Kitagawa Y
Breast J; 2020 Sep; 26(9):1765-1770. PubMed ID: 32449173
[TBL] [Abstract][Full Text] [Related]
25. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis.
O'Connor DJ; Davey MG; Barkley LR; Kerin MJ
Breast; 2022 Feb; 61():1-10. PubMed ID: 34864494
[TBL] [Abstract][Full Text] [Related]
26. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
27. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.
Mathieu MC; Rouzier R; Llombart-Cussac A; Sideris L; Koscielny S; Travagli JP; Contesso G; Delaloge S; Spielmann M
Eur J Cancer; 2004 Feb; 40(3):342-51. PubMed ID: 14746851
[TBL] [Abstract][Full Text] [Related]
28. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
[TBL] [Abstract][Full Text] [Related]
29. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.
Rakha EA; El-Sayed ME; Powe DG; Green AR; Habashy H; Grainge MJ; Robertson JF; Blamey R; Gee J; Nicholson RI; Lee AH; Ellis IO
Eur J Cancer; 2008 Jan; 44(1):73-83. PubMed ID: 18035533
[TBL] [Abstract][Full Text] [Related]
30. Post-Mastectomy Radiation Therapy for Invasive Lobular Carcinoma: A Comparative Utilization and Outcomes Study.
Stecklein SR; Shen X; Mitchell MP
Clin Breast Cancer; 2016 Aug; 16(4):319-26. PubMed ID: 26943990
[TBL] [Abstract][Full Text] [Related]
31. Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast.
Arps DP; Healy P; Zhao L; Kleer CG; Pang JC
Breast Cancer Res Treat; 2013 Apr; 138(3):719-26. PubMed ID: 23535842
[TBL] [Abstract][Full Text] [Related]
32. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
Lips EH; Mukhtar RA; Yau C; de Ronde JJ; Livasy C; Carey LA; Loo CE; Vrancken-Peeters MJ; Sonke GS; Berry DA; Van't Veer LJ; Esserman LJ; Wesseling J; Rodenhuis S; Shelley Hwang E;
Breast Cancer Res Treat; 2012 Nov; 136(1):35-43. PubMed ID: 22961065
[TBL] [Abstract][Full Text] [Related]
33. Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival.
García-Fernández A; Lain JM; Chabrera C; García Font M; Fraile M; Barco I; Torras M; Reñe A; González S; González C; Piqueras M; Veloso E; Cirera L; Pessarrodona A; Giménez N
Breast J; 2015; 21(5):533-7. PubMed ID: 26190560
[TBL] [Abstract][Full Text] [Related]
34. Comparative evaluation of nuclear and histological grades as prognostic factors for invasive breast cancer.
Oshiro C; Yamasaki M; Noda Y; Nishimae A; Takahashi H; Inaji H
Breast Cancer; 2020 Sep; 27(5):947-953. PubMed ID: 32297249
[TBL] [Abstract][Full Text] [Related]
35. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
[TBL] [Abstract][Full Text] [Related]
36. Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section.
Tsuda H; Akiyama F; Kurosumi M; Sakamoto G; Watanabe T
Jpn J Clin Oncol; 1998 Aug; 28(8):486-91. PubMed ID: 9769782
[TBL] [Abstract][Full Text] [Related]
37. Infiltrating lobular carcinoma of the breast: systemic treatment.
Farese SA; Aebi S
Breast Dis; 2008-2009; 30():45-52. PubMed ID: 19850995
[TBL] [Abstract][Full Text] [Related]
38. Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma.
Adachi Y; Sawaki M; Hattori M; Yoshimura A; Gondo N; Kotani H; Iwase M; Kataoka A; Onishi S; Sugino K; Terada M; Horisawa N; Mori M; Oze I; Iwata H
Breast Cancer; 2018 Sep; 25(5):560-565. PubMed ID: 29536376
[TBL] [Abstract][Full Text] [Related]
39. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Moran MS; Yang Q; Haffty BG
Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
[TBL] [Abstract][Full Text] [Related]
40. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
